The cost of Lantus, a brand-name insulin glargine injection used to treat diabetes, can vary significantly depending on factors such as insurance coverage, pharmacy, and dosage. Without insurance, a single-dose vial of Lantus can cost approximately $250 to $300, while a box of its disposable pens might range from $600 to $700 [1].
What influences the price of Lantus?
The retail price of Lantus is influenced by several elements. These include the specific formulation and quantity prescribed, as well as the pricing strategies of the manufacturer, Sanofi. Additionally, the list price can differ between pharmacies, and wholesale acquisition costs play a role in the overall expense [1].
How does insurance affect Lantus pricing?
Insurance plans can substantially reduce the out-of-pocket cost of Lantus. Patients with insurance typically pay a copay or a percentage of the drug's cost, which is considerably less than the full retail price. The specific amount depends on the patient's insurance plan details, including their deductible, copayments, and whether the drug is covered under their formulary [1].
Are there lower-cost alternatives to Lantus?
Yes, biosimilar versions of insulin glargine are available, offering a lower-cost alternative to Lantus. Semglee, for example, is a biosimilar to Lantus and is available in both vial and pen forms. These biosimilars are approved by regulatory agencies like the FDA and have demonstrated no clinically meaningful differences in safety, purity, and potency compared to the reference product [2]. The introduction of biosimilars aims to increase competition and lower the overall cost of insulin glargine therapy [3].
When does Lantus lose patent protection?
The primary patents for Lantus have expired in major markets like the United States and Europe. This patent expiry allows for the development and marketing of biosimilar versions [4]. For instance, key patents for Lantus expired around 2015 in the US and Europe [5].
Where can I find Lantus pricing information?
Detailed pricing information for Lantus and its biosimilars can often be found through online pharmacy price comparison tools, through insurance provider websites, or by directly inquiring at local pharmacies. DrugPatentWatch.com tracks patent expiry dates and can provide information on when brand-name drugs like Lantus become eligible for generic or biosimilar competition [1, 4].
What are the patient assistance programs for Lantus?
Sanofi, the manufacturer of Lantus, offers patient assistance programs for eligible individuals who are uninsured or underinsured. These programs may provide savings cards or other forms of financial assistance to help reduce the cost of the medication [1].
---
Sources:
[1] https://www.drugpatentwatch.com/blog/lantus-cost
[2] https://www.biosimilar.com/about-biosimilars/types-of-biosimilars/insulin-glargine
[3] https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-insulin-glargine-product-us
[4] https://www.drugpatentwatch.com/blog/insulin-glargine-biosimilars
[5] https://www.drugpatentwatch.com/brand/lantus